Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Circulation

• Publication date

  2005-09-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.105.549121PMID 16172283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.

  2005cited by this paper
• Erythropoietin in cardiovascular diseases.

  2004cited by this paper
• Anemia as a risk factor and therapeutic target in heart failure.

  2004cited by this paper
• Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.

  2004cited by this paper
• Are hematinic deficiencies the cause of anemia in chronic heart failure?

  2004cited by this paper
• Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE).

  2003cited by this paper
• Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure

  2003cited by this paper
• Angiotensin-Converting Enzyme Gene Polymorphism and Erythropoietin Requirement

  2003cited by this paper
• Effects of an Angiotensin II Receptor Antagonist and Angiotensin-Converting Enzyme Inhibitors on Burst Forming Units-Erythroid in Chronic Hemodialysis Patients

  2003cited by this paper
• Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.

  2002cited by this paper
• Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes?

  2002cited by this paper
• Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial

  2002cited by this paper
• COMPARISON OF THE EFFECTS OF ENALAPRIL AND LOSARTAN ON POSTTRANSPLANTATION ERYTHROCYTOSIS IN RENAL TRANSPLANT RECIPIENTS: Prospective Randomized Study1

  2001cited by this paper
• Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements.

  2001cited by this paper
• Guidelines for the diagnosis and treatment of chronic heart failure.

  2001cited by this paper
• Serum erythropoietin in heart failure patients treated with ACE‐inhibitors or AT1 antagonists

  2000cited by this paper
• Renal function, neurohormonal activation, and survival in patients with chronic heart failure.

  2000cited by this paper
• Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis.

  1999cited by this paper
• Effects of the angiotensin‐converting enzyme inhibitor enalapril on blood haematopoietic progenitors and Acetyl‐N‐Ser‐Asp‐Lys‐Pro concentrations

  1997cited by this paper
• Angiotensin II stimulates proliferation of normal early erythroid progenitors.

  1997cited by this paper
• Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.

  1996cited by this paper
• The Hemoregulatory Peptide N-Acetyl-Ser-Asp-Lys-Pro Is a Natural and Specific Substrate of the N-terminal Active Site of Human Angiotensin-converting Enzyme (*)

  1995cited by this paper
• Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension.

  1995cited by this paper
• PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1).

  1992cited by this paper
• Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers.

  1992cited by this paper
• Prediction of creatinine clearance from plasma creatinine: comparison of five formulae.

  1989cited by this paper
• Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure.

  1989cited by this paper
• The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure.

  1988cited by this paper
• Captopril in heart failure. A double blind controlled trial.

  1984cited by this paper
• Enalapril (MK-421) and the white cell count and haematocrit.

  1982cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Thymosin beta 4: An Emerging Therapeutic Candidate for Kidney Diseases.

  2026cites this paper
• UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease

  2025cites this paper
• Prognostic Value of Reticulocyte Production Ability in Patients with Chronic Heart Failure.

  2025cites this paper
• Anemia in cardiorenal disease: From pathogenesis to treatment.

  2025cites this paper
• Functional Iron Deficiency in Patients With Heart Failure: A Focus on Its Prevalence Among Hospitalized Patients and Short-Term Outcomes

  2025cites this paper
• Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study

  2024cites this paper
• The effect of the four pharmacological pillars of heart failure on haemoglobin level

  2024cites this paper
• Hematological parameters of hypertensive patients in northeast Ethiopia: A comparative cross-sectional study

  2024cites this paper
• Prognostic value of the diagnosis of anemia in patients with heart failure: an analysis based on the Colombian heart failure registry (RECOLFACA)

  2024cites this paper
• Comorbid normochromic and normocytic anemia in coronary artery disease: retrospective study

  2023cites this paper
• Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.

  2023cites this paper
• How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome

  2023cites this paper
• Iron Dyshomeostasis and Mitochondrial Function in the Failing Heart: A Review of the Literature

  2023cites this paper
• Prognostic implication of hemoglobin reduction with and without clinical bleeding after percutaneous coronary intervention in patients with acute coronary syndromes

  2023cites this paper
• Intravenous Iron Technique Evaluation in Chronic Heart Failure With Iron Deficiency Anemia

  2023cites this paper
• Can Iron Play a Crucial Role in Maintaining Cardiovascular Health in the 21st Century?

  2022cites this paper
• Anemia and Heart Failure: A Narrative Review

  2022cites this paper
• In-hospital mortality rate and predictors of 30-day readmission in patients with iron deficiency anemia and diastolic heart failure: A cross-sectional study

  2022cites this paper
• Post percutaneous coronary intervention hemoglobin levels predict in-hospital mortality in patients with STEMI treated with primary percutaneous coronary intervention.

  2021cites this paper
• Anaemia in Heart Failure Patients, Associated with Angiotensin – Renin – Aldosterone System Altering Medications

  2021cites this paper
• Impact on Longevity of Genetic Cardiovascular Risk and Lifestyle including Red Meat Consumption

  2020cites this paper
• Анемия у больных с хронической сердечной недостаточностью: современное состояние проблемы

  2019cites this paper
• [Position Paper. The role of iron deficiency in patients with chronic heart failure and current corrective approaches].

  2019cites this paper
• The Influence of Cardiovascular Medications on Iron Metabolism in Patients with Heart Failure

  2019cites this paper
• [Anaemia and iron deficiency in chronic heart failure patients].

  2019cites this paper
• Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated

  2019cites this paper
• Anemia in heart failure - from guidelines to controversies and challenges

  2018cites this paper
• DEPTH Anemia and Iron Deficiency in Heart Failure Current Concepts and Emerging Therapies

  2018cites this paper
• Sodium restriction on top of RAAS blockade increases circulating levels of n-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients

  2018cites this paper
• Erythropoietin response to anaemia in heart failure

  2018cites this paper
• Hypertension and longevity: role of genetic polymorphisms in renin-angiotensin-aldosterone system and endothelial nitric oxide synthase

  2018cites this paper
• Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies

  2018cites this paper
• The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.

  2018cites this paper
• Aerobic exercise training differentially affects ACE C- and N-domain activities in humans: Interactions with ACE I/D polymorphism and association with vascular reactivity

  2018cites this paper
• Anemia in Heart Failure: Still Relevant?

  2017cites this paper
• Najčešći komorbiditeti u bolesnika sa zatajivanjem srca

  2017cites this paper
• The importance of haemoglobin to physical function

  2017cites this paper
• Management of anemia in patients with congestive heart failure

  2017cites this paper
• Comorbidities in Heart Failure.

  2017cites this paper
• Clinical Implications of Plasma N-acetyl-seryl-aspartyl-lysyl-proline Level in Stable Kidney Transplant Recipients.

  2016cites this paper
• Treatment of Anemia in Cardiorenal Syndrome

  2016cites this paper
• Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia

  2016cites this paper
• Erythropoietin, Hemoglobin and Endothelial Progenitor Cell Levels in Patients with Acute Myocardial Infarction

  2015cites this paper
• Clinical Aspects of Cardiorenal Syndrome: Consequences of Therapy with the Renin-Angiotensin System Inhibitors

  2015cites this paper
• N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.

  2015cites this paper
• The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications.

  2015cites this paper
• Vincent M. van DeursenKevin DammanPeter van der Meer • Peter J. WijkstraGert-Jan LuijckxAndre van BeekDirk J. van Veldhuisen •

  2014cites this paper
• Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black.

  2014cites this paper
• A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia

  2014influential citation
• Significant decrease in plasma N-acetyl-seryl-aspartyl-lysyl-proline level in patients with end stage renal disease after kidney transplantation.

  2014cites this paper
• Co-morbidities in heart failure

  2014cites this paper
• [Clinical manifestations of anemia syndrome and its significance in the course of chronic heart failure in elderly patients].

  2014influential citation
• Anemia and erythropoietin in cardiovascular disease

  2014cites this paper
• Iron deficiency anemia in heart failure

  2013cites this paper
• Kidney function and congestive heart failure. The Norwegian perspective.

  2013cites this paper
• Iron deficiency in chronic heart failure with severely depressed systolic left ventricular function

  2013cites this paper
• The influence of vitamin E bonded haemodialysis membranes on erythropoiesis stimulating agent requirements, oxidative stress, inflammation, haemostasis and outcomes

  2013cites this paper
• Procjena stupnja anemije u bolesnika nakon zamjene srčanih zalistaka i aortokoronarnog premoštenja The estimation of anemia degree in patients after heart valve replacement and coronary artery bypass surgery

  2013cites this paper
• Erythropoietin and heart failure: the end of a promise?

  2013cites this paper
• Anemia associated with chronic heart failure: current concepts

  2013cites this paper
• The Role of Treatment for Anemia as a Therapeutic Target in the Management of Chronic Heart Failure: Insights After RED-HF

  2013cites this paper
• Iron deficiency in chronic heart failure: an international pooled analysis.

  2013cites this paper
• Sodium restriction on top of renin–angiotensin–aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients

  2013cites this paper
• Treatment Options Anemia in Chronic Heart Failure : Prevalence, Etiology, Clinical Correlates, and

  2013cites this paper
• The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure.

  2013cites this paper
• Suppression of erythropoiesis in patients with chronic heart failure and anaemia of unknown origin: evidence of an immune basis.

  2013cites this paper
• The estimation of anemia degree in patients after heart valve replacement and coronary artery bypass surgery

  2013cites this paper
• Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry.

  2012cites this paper
• Iron therapy alone or in combination with erythropoietin in surgical and medical cardiac patients

  2012cites this paper
• Anemia in heart failure.

  2012cites this paper
• Novel therapies in acute and chronic heart failure.

  2012cites this paper
• Inhibition of the Renin Angiotensin System during Autologous Stem Cell Transplant Does Not Impact Time to Engraftment

  2012cites this paper
• Tratamiento de la anemia en el síndrome cardiorrenal

  2012cites this paper
• Establishment and clinical application of a highly sensitive enzyme immunoassay for determination of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline

  2012cites this paper
• Tratamiento de la anemia en el síndrome cardiorrenal

  2012cites this paper
• On-line solid-phase extraction LC-MS/MS for the determination of Ac-SDKP peptide in human plasma from hemodialysis patients.

  2012cites this paper
• Inflammation and anaemia in a broad spectrum of patients with heart failure

  2012cites this paper
• Interaction of anemia and decrease in renal function on survival of patients with heart failure.

  2012cites this paper
• Effect of anemia on short- and long-term outcome in patients hospitalized for acute coronary syndromes.

  2012cites this paper
• An early percutaneous catheter-mounted valve

  2011cites this paper
• Anaemia and heart failure

  2011cites this paper
• Erythropoiesis-stimulating agents and heart failure.

  2011cites this paper
• Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

  2011cites this paper
• Papel do sistema renina angiotensina sobre as adaptações eritropoiéticas induzidas pelo treinamento físico aeróbico

  2011cites this paper
• Anemia and response to erythropoietin in the cardiorenal syndrome

  2011cites this paper
• Prognostic importance of comorbidities in heart failure with preserved left ventricular ejection fraction

  2011cites this paper
• Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry.

  2011cites this paper
• Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial

  2011cites this paper
• Erythropoietin and the heart: facts and perspectives.

  2011cites this paper
• Patogênese da anemia em pacientes com insuficiência cardíaca : contribuição de mecanismos inflamatórios, peculiaridades do metabolismo do ferro e ação da eritropoetina

  2010cites this paper
• Anemia in heart failure: should we supplement iron in patients with chronic heart failure?

  2010cites this paper
• Bone marrow dysfunction in chronic heart failure patients

  2010cites this paper
• The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients

  2010cites this paper
• Prevalence of chronic kidney disease and anemia in patients with coronary artery disease with normal serum creatinine undergoing percutaneous coronary interventions: relation to New York Heart Association class.

  2010cites this paper
• Pathophysiology of anemia in heart failure.

  2010cites this paper
• Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin

  2010cites this paper
• Mediators of anemia in chronic heart failure.

  2010cites this paper
• Plasma Kallikrein and Angiotensin I-converting enzyme N- and C-terminal domain activities are modulated by the insertion/deletion polymorphism.

  2010cites this paper
• Impact of erythropoiesis‐stimulating agents on morbidity and mortality in patients with heart failure: an updated, post‐TREAT meta‐analysis

  2010cites this paper
• Therapie der fortgeschrittenen Herz - insuffizienz: medikamentös, Resynchronisation (CRT), Operation

  2010cites this paper